CAR T
EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma
October 20, 2020Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma
Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …
Oncology research in the age of COVID-19
September 14, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, pharma
Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive …
FDA approves Phase 1 trial for HIV gene therapy
August 24, 2020Sales and Marketing CAR T, CAR T cancer therapies, CAR-T
The FDA has approved a request from American Gene Technologies to begin a clinical study into its HIV gene therapy. …
Poseida suspends CAR T therapy trial in prostate cancer due to patient death
August 18, 2020Manufacturing and Production, Research and Development CAR T, CAR-T, Poseida, patient death, pharma
Poseida’s Phase 1 trial that used an investigational CAR T therapy for treating prostate cancer has been suspended due to …
CAR T cell therapy is revolutionising cancer treatment, but at what cost?
August 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature
CAR T cell therapy is one of the latest innovations in gene therapy. The process is primarily used to treat …
Kite secures FDA approval for second CAR T therapy Tecartus in relapsed or refractory mantle cell lymphoma
July 27, 2020Sales and Marketing CAR T, CAR-T, FDA, Gilead, kite pharma
Kite Pharma has chalked up another regulatory success for its parent company Gilead with the news that the FDA has …
100% of multiple myeloma patients respond to Janssen’s investigational CAR T therapy, data shows
May 14, 2020Research and Development CAR T, CAR-T, Janssen, multiple myeloma, pharma
Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell …
Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma
October 8, 2019Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma
News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor …
Top Ten most popular articles on Pharmafile.com this week!
August 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, CAR T, CAR-T, Eli Lilly, Lexicon, Medicare, Novartis, Pfizer, Sanofi, pharma
This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …
Novartis’ Kymriah to be covered by Japan’s national insurance system
May 16, 2019Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma
Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …
Canada Health approves Novartis’ CAR-T therapy Kymriah
January 18, 2019Medical Communications CAR T, CAR-T, Canada, Cancer, Kymriah, Novartis, oncology
Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and …
Merck KGaA hands over CAR-T therapy business to Intrexon in deal worth $175 million
December 20, 2018Business Services, Medical Communications, Sales and Marketing CAR T, CAR-T, Cancer, Germany, Intrexon, Merck KGaA, darmstadt, oncology
German pharma firm Merck KGaA has agreed to hand over its CAR-T therapy business to US company Intrexon in a …
20 year old man died after leukaemia cell was accidently mixed into CAR T therapy
October 2, 2018Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology
A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …
Novartis strike $40m deal with Chinese firm Cellular Biomedicine
September 28, 2018Medical Communications CAR T, CAR-T, China, Kymriah, Novartis, cellular biomedicine, prc
Swiss multinational Novartis have paired up with Chinese drugmaker Cellular Biomedicine (CBMG) in order to manufacture CAR-T therapy Kymriah in …
NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process
September 25, 2018Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing
Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …
